4-isobutylmethylaminophenol monohydrochloride | 552849-44-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-isobutylmethylaminophenol monohydrochloride
• 英文别名: 4-[Methyl(2-methylpropyl)amino]phenol;hydrochloride
• CAS: 552849-44-2
• 化学式: C₁₁H₁₇NO*ClH
• 分子量: 215.723
• InChiKey: VCQIEEQNQDRSAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.91
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  23.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl (5-chloro-2-nitrophenyl)(methyl)carbamate 、 4-isobutylmethylaminophenol monohydrochloride 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.25h， 生成 N-(5-(4-(isobutyl-methyl-amino)phenoxy)-2-nitrophenyl)methylamine
  参考文献：
  名称：

  EP1982718

  摘要：

  公开号：
• 作为产物：
  描述：

  (4-(isobutyl-methyl-amino)phenoxy)-t-butyldimethylsilane 在 四丁基氟化铵 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 生成 4-isobutylmethylaminophenol monohydrochloride
  参考文献：
  名称：

  EP1982718

  摘要：

  公开号：

文献信息

• Anti-cancer pharmaceutical compositions and methods for treating patients with cancer
  申请人：Fujiwara Kosaku

  公开号：US20090028868A1

  公开（公告）日：2009-01-29

  Method of treating persons having carcinoma, sarcoma or hematopoietic cancer by administering (i) a compound of the formula (I) and (ii) an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and pharmaceutical compositions for use in said method. A method for treating gastric cancer, colon cancer, lung cancer, breast cancer, pancreas cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma and leukemia by administering a compound of the formula (I).

  通过给予公式（I）的化合物和表皮生长因子受体（EGFR）抑制剂、血管内皮生长因子受体（VEGFR）抑制剂以及用于该方法的制药组合物来治疗患有癌症、肉瘤或造血系统癌症的人的方法。通过给予公式（I）的化合物来治疗胃癌、结肠癌、肺癌、乳腺癌、胰腺癌、肾癌、前列腺癌、髓母细胞瘤、横纹肌肉瘤、尤因肉瘤、脂肪肉瘤、多发性骨髓瘤和白血病的方法。
• METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG
  申请人：FUJIWARA Kosaku

  公开号：US20120258991A1

  公开（公告）日：2012-10-11

  A method of treating a cancer selected from the group consisting of breast cancer, pancreatic cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma or leukemia. An effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride is administered to a patient having said cancer.

  一种治疗乳腺癌、胰腺癌、肾癌、前列腺癌、髓母细胞瘤、横纹肌肉瘤、尤因氏肉瘤、脂肪肉瘤、多发性骨髓瘤或白血病的方法。向患有该癌症的患者给予有效量的5-(4-(6-(4-氨基-3,5-二甲基苯氧基)-1-甲基-1H-苯并咪唑-2-基甲氧基)-苄基)-噻唑烷-2,4-二酮·二盐酸盐。
• METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD
  申请人：FUJIWARA Kosaku

  公开号：US20120263716A1

  公开（公告）日：2012-10-18

  The method of treating a person having a cancer selected from carcinoma, sarcoma or hematopoietic cancer by administering (a) an effective amount of at least one anti-cancer drug selected from the group consisting of an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and a Raf kinase inhibitor and (b) an effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride provided that said carcinoma is not lung cancer when an EGFR inhibitor is erlotinib. The invention also provides a pharmaceutical composition that may be used in practicing said method.

  通过给予（a）至少一种抗癌药物，所述抗癌药物被选择自表皮生长因子受体（EGFR）抑制剂、血管内皮生长因子受体（VEGFR）抑制剂和Raf激酶抑制剂中的至少一种有效量和（b）5-（4-（6-（4-氨基-3,5-二甲基-苯氧基）-1-甲基-1H-苯并咪唑-2-基甲氧基）-苄基）-噻唑烷-2,4-二酮二盐酸盐的有效量来治疗患有癌症的人，所述癌症被选择自癌瘤、肉瘤或造血系统癌症，但当使用EGFR抑制剂Erlotinib时，所述癌症不是肺癌。本发明还提供了一种可用于实施该方法的药物组成物。
• METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20130183297A1

  公开（公告）日：2013-07-18

  The method of treating a person having a cancer selected from carcinoma, sarcoma or hematopoietic cancer by administering (a) an effective amount of at least one anti-cancer drug selected from the group consisting of an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and a Raf kinase inhibitor and (b) an effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride provided that said carcinoma is not lung cancer when an EGFR inhibitor is erlotinib. The invention also provides a pharmaceutical composition that may be used in practicing said method.

  本发明提供了一种治疗患有癌症的方法，所述癌症选自癌瘤、肉瘤或造血系统癌症，通过给予（a）有效量的至少一种抗癌药物，所述抗癌药物选自表皮生长因子受体（EGFR）抑制剂、血管内皮生长因子受体（VEGFR）抑制剂和Raf激酶抑制剂组成，以及（b）有效量的5-（4-（6-（4-氨基-3,5-二甲基-苯氧基）-1-甲基-1H-苯并咪唑-2-基甲氧基）苄基）噻唑烷-2,4-二酮二盐酸盐，前提是当使用EGFR抑制剂erlotinib时，所述癌瘤不是肺癌。本发明还提供了一种可用于实施该方法的制药组合物。
• ANTI-CANCER PHARMACEUTICAL COMPOSITION
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1982718A1

  公开（公告）日：2008-10-22

  [Object] An object is to provide an anti-cancer pharmaceutical composition for prophylaxis or treatment of carcinoma, sarcoma or hematopoietic cancer. [Means to Solve the Problem] An anti-cancer pharmaceutical composition comprising a compound represented by the following general formula (I): [wherein, R represents a phenyl group substituted with 1 to 5 substituents selected from a halogen atom; a hydroxy group; a C1-C6 alkyl group; a halogeno C1-C6 alkyl group; a C1-C6 alkoxy group; a C1-C6 alkylthio group; an amino group which may be substituted with a substituent; a C3-C10 cycloalkyl, C6-C10 aryl, C7-C16 aralkyl, C6-C10 aryloxy, C7-C16 aralkyloxy and C6-C10 arylthio group which may be substituted with a substituent; a C1-C7 aliphatic acyloxy group; a 4- to 7-membered saturated heterocyclic group containing nitrogen atom(s); a 5- or 6-membered aromatic heterocyclic group containing nitrogen atom(s); a nitro group; and a cyano group; and X represents an oxygen atom or a sulfur atom] or a pharmacologically acceptable salt thereof, as an active ingredient, and an anti-cancer pharmaceutical composition for prophylaxis or treatment of carcinoma, sarcoma or hematopoietic cancer which is for administering simultaneously or separately at different times, containing an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor or a Raf kinase inhibitor; and a compound represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient. [Selected Drawings]

  目的 目的是提供一种用于预防或治疗癌、肉瘤或造血癌的抗癌药物组合物。 [解决问题的方法］ 一种抗癌药物组合物，包含由以下通式（I）代表的化合物： 其中 R 代表被 1 至 5 个取代基取代的苯基，取代基选自卤素原子；羟基；C1-C6 烷基；卤代 C1-C6 烷基；C1-C6 烷氧基；C1-C6 烷硫基；可被取代基取代的氨基；可被取代基取代的 C3-C10 环烷基、C6-C10 芳基、C7-C16 芳烷基、C6-C10 芳氧基、C7-C16 芳氧基和 C6-C10 芳硫基； C1-C7 脂肪族酰氧基；含氮原子的 4-7 元饱和杂环基；含氮原子的 5 或 6 元芳香杂环基；硝基；和氰基；和 X代表氧原子或硫原子]或其药理上可接受的盐，作为活性成分、 以及 一种用于预防或治疗癌、肉瘤或造血癌的抗癌药物组合物，可在不同时间同时或分别给药，该组合物含有表皮生长因子受体（EGFR）抑制剂、血管内皮生长因子受体（VEGFR）抑制剂或 Raf 激酶抑制剂；以及一种由上述通式（I）代表的化合物或其药理学上可接受的盐作为活性成分。 附图